Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

AMGN plainly spent more on the Humira litigation than MNTA can afford. We can get some idea by looking at the “Other” operating expenses line (where legal expenses go) on AMGN’s 3Q17 income statement: https://www.sec.gov/Archives/edgar/data/318154/000031815417000027/amgn-2017930x10q.htm#s931823CDC31C505483EF191450576C45 .

2017 year-to-date (i.e. 9-month) “other” expenses were $347M, versus $121M in the comparable 2016 period. It’s reasonable to surmise that most of the $236M increase in this line item from 2016 to 2017 is attributable to the ABBV litigation.